Arcturus Therapeutics Holdings Inc. (ARCT) — 8-K Filings

8-K Filings (20)

• Arcturus Therapeutics Files 8-K on Officer/Director Changes — Dec 15, 2025 Risk: medium
  Arcturus Therapeutics Holdings Inc. filed an 8-K on December 15, 2025, reporting events as of December 11, 2025. The filing pertains to the departure of directo
• 8-K Filing — Nov 10, 2025
• Arcturus Therapeutics Files 8-K — Oct 22, 2025 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on October 22, 2025, reporting on various events. The filing includes information related to financial statemen
• Arcturus Therapeutics Files 8-K — Sep 26, 2025 Risk: medium
  Arcturus Therapeutics Holdings Inc. filed an 8-K on September 26, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing d
• Arcturus Therapeutics Files 8-K — Aug 29, 2025 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on August 29, 2025, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing d
• Arcturus Therapeutics Files 8-K on Financials — Aug 11, 2025 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on August 11, 2025, reporting on its results of operations and financial condition. The filing includes financi
• Arcturus Therapeutics Files 8-K — Jun 30, 2025 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on June 30, 2025, reporting on financial statements and exhibits. The filing does not contain specific financia
• Arcturus Therapeutics Files 8-K on Shareholder Votes — Jun 6, 2025 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on June 6, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain
• Arcturus Therapeutics Files 8-K on Financials — May 12, 2025 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition, as well as financial statement
• Arcturus Therapeutics Files 8-K on Financials — Mar 6, 2025 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on March 6, 2025, reporting on its results of operations and financial condition. The filing includes financial
• Arcturus Therapeutics Files 8-K on Financials — Nov 7, 2024 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition. The filing includes financ
• Arcturus Therapeutics Files 8-K — Aug 13, 2024 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on August 13, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing d
• Arcturus Therapeutics Files 8-K on Financials — Aug 5, 2024 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on August 5, 2024, reporting on its results of operations and financial condition. The filing includes financia
• Arcturus Therapeutics Announces Board and Executive Changes — Jun 24, 2024 Risk: medium
  Arcturus Therapeutics Holdings Inc. announced on June 19, 2024, changes in its board of directors and executive compensation. The company filed an 8-K form deta
• Arcturus Therapeutics Appoints New CBO, Elects Director — Jun 14, 2024 Risk: medium
  Arcturus Therapeutics Holdings Inc. announced on June 14, 2024, the appointment of Dr. Steven Yi as Chief Business Officer and the election of Dr. Charles L.SA.
• Arcturus Therapeutics Files 8-K on Financials — May 8, 2024 Risk: medium
  Arcturus Therapeutics Holdings Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition, as well as financial statements
• Arcturus Therapeutics Changes Independent Auditor — Apr 5, 2024 Risk: low
  Arcturus Therapeutics Holdings Inc. announced on April 5, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and
• Arcturus Therapeutics Partners with Ultragenyx for Cystic Fibrosis Drug — Mar 19, 2024 Risk: medium
  Arcturus Therapeutics Holdings Inc. announced on March 19, 2024, that it has entered into a clinical supply agreement with Ultragenyx Pharmaceutical Inc. for it
• Arcturus Therapeutics Files 8-K on Financials — Mar 7, 2024 Risk: medium
  Arcturus Therapeutics Holdings Inc. filed an 8-K on March 7, 2024, reporting on its results of operations and financial condition. The filing includes financial
• Arcturus Therapeutics Reports Executive Compensation Changes — Feb 23, 2024 Risk: low
  Arcturus Therapeutics Holdings Inc. filed an 8-K on February 23, 2024, reporting events from February 20, 2024. The filing primarily concerns changes in compens

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX